Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new version (v3.6.6) dated 2026-08-27 updates the Document Section, Study Design, Study Status, and Recruitment Status. This change replaces the prior Active, not recruiting status from the previous revision and marks the study as Completed, reflecting its current lifecycle stage in the study record.SummaryDifference0.6%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe record history now shows the latest site revision, v3.6.5, added to the log. The prior revision, v3.6.4, is removed from the log.SummaryDifference0.1%

- Check49 days agoChange DetectedThe footer revision label updated from v3.6.3 to v3.6.4, indicating a small version update to the page. The change is cosmetic and does not modify the study records or functionality.SummaryDifference0.1%

- Check71 days agoChange DetectedA new revision entry, Revision: v3.6.3, was added to the record history, replacing the previous v3.6.2. This updates the page's revision metadata without altering the study data.SummaryDifference0.1%

- Check78 days agoChange DetectedA new history entry (Version 35) with a Study Status update and revision v3.6.2 was added to the study record on 2026-06-24, and the older revision v3.6.0 was removed on 2026-06-10.SummaryDifference0.3%

- Check92 days agoChange DetectedRecruitment status updated to No longer looking for participants, indicating enrollment has closed for this study. This update is logged under Revision: v3.6.0 on 2026-06-10.SummaryDifference1%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.